AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a US and China based clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), closed a USD 73 million Series B financing.
The round was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, as well as continued participation from existing investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital.
The proceeds will fund the continued Phase 2 development of AHB-137, AusperBio’s lead investigational therapy, supporting both clinical studies in China and global trials, as well as the development of commercial-scale manufacturing processes. The funding will also facilitate the expansion of the company’s therapeutic pipeline and operational capabilities to drive sustained growth.
Led by Dr. Guofeng Cheng, co-founder and CEO, and Dr. Chris Yang, co-founder and CSO, AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for therapies, with an initial focus on curing chronic hepatitis B infection. The company has developed a proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
AHB-137, a novel unconjugated antisense oligonucleotide (ASO) developed within AusperBio’s proprietary Med-Oligo™ ASO technology platform, was designed to treat chronic hepatitis B for a functional cure. Its preclinical and Phase 1 clinical data were highlighted at the 2023 EASL conference and the 2024 EASL conference, respectively. This novel dual-mechanism ASO has completed its global Phase 1b trial and is now undergoing multiple Phase 2 trials in China. With its global development strategy, AHB-137 is advancing rapidly toward the goal of an HBV cure.
FinSMEs
27/12/2024